Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital Changes
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Cash from Investing Activities (2016 - 2025)

Historic Cash from Investing Activities for China Pharma Holdings (CPHI) over the last 17 years, with Q3 2025 value amounting to -$40598.0.

  • China Pharma Holdings' Cash from Investing Activities fell 54032.54% to -$40598.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$404336.0, marking a year-over-year decrease of 59400.8%. This contributed to the annual value of -$291718.0 for FY2024, which is 243293.39% down from last year.
  • China Pharma Holdings' Cash from Investing Activities amounted to -$40598.0 in Q3 2025, which was down 54032.54% from -$9921.0 recorded in Q2 2025.
  • China Pharma Holdings' Cash from Investing Activities' 5-year high stood at $55964.0 during Q1 2023, with a 5-year trough of -$415977.0 in Q3 2021.
  • Its 5-year average for Cash from Investing Activities is -$82108.7, with a median of -$9921.0 in 2025.
  • Its Cash from Investing Activities has fluctuated over the past 5 years, first surged by 412329.26% in 2023, then plummeted by 592721.45% in 2024.
  • Quarter analysis of 5 years shows China Pharma Holdings' Cash from Investing Activities stood at -$7056.0 in 2021, then soared by 486.45% to $27268.0 in 2022, then crashed by 116.6% to -$4527.0 in 2023, then crashed by 5927.21% to -$272852.0 in 2024, then soared by 85.12% to -$40598.0 in 2025.
  • Its Cash from Investing Activities was -$40598.0 in Q3 2025, compared to -$9921.0 in Q2 2025 and -$80965.0 in Q1 2025.